AP2005003262A0 - Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. - Google Patents
Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.Info
- Publication number
- AP2005003262A0 AP2005003262A0 AP2005003262A AP2005003262A AP2005003262A0 AP 2005003262 A0 AP2005003262 A0 AP 2005003262A0 AP 2005003262 A AP2005003262 A AP 2005003262A AP 2005003262 A AP2005003262 A AP 2005003262A AP 2005003262 A0 AP2005003262 A0 AP 2005003262A0
- Authority
- AP
- ARIPO
- Prior art keywords
- tgf
- inhibitors
- growth factor
- isoxazole compounds
- tranforming growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41213102P | 2002-09-18 | 2002-09-18 | |
US48458003P | 2003-07-02 | 2003-07-02 | |
PCT/IB2003/004005 WO2004026865A1 (en) | 2002-09-18 | 2003-09-12 | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2005003262A0 true AP2005003262A0 (en) | 2005-03-31 |
Family
ID=32033584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2005003262A AP2005003262A0 (en) | 2002-09-18 | 2003-09-12 | Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. |
Country Status (25)
Country | Link |
---|---|
US (1) | US7030125B2 (es) |
EP (1) | EP1542995A1 (es) |
JP (1) | JP2006506443A (es) |
KR (1) | KR20050057441A (es) |
CN (1) | CN1681809A (es) |
AP (1) | AP2005003262A0 (es) |
AR (1) | AR041275A1 (es) |
AU (1) | AU2003263431A1 (es) |
BR (1) | BR0314286A (es) |
CA (1) | CA2499332A1 (es) |
CO (1) | CO5550458A2 (es) |
EA (1) | EA200500286A1 (es) |
EC (1) | ECSP055685A (es) |
HR (1) | HRP20050246A2 (es) |
IS (1) | IS7695A (es) |
MA (1) | MA27444A1 (es) |
MX (1) | MXPA05002378A (es) |
NO (1) | NO20051852L (es) |
OA (1) | OA12925A (es) |
PA (1) | PA8583101A1 (es) |
PE (1) | PE20050076A1 (es) |
PL (1) | PL375973A1 (es) |
TW (1) | TW200410954A (es) |
UY (1) | UY27983A1 (es) |
WO (1) | WO2004026865A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0314302A (pt) * | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
JP4547271B2 (ja) | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物 |
AU2003256003A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
CN101084212A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
CN101142198B (zh) | 2005-02-17 | 2012-10-31 | 辛塔制药公司 | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 |
CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Alk5 조절제를 사용한 안압의 조절 |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基***并吡啶,其組合物及使用其之治療方法 |
NZ713219A (en) | 2013-03-14 | 2017-04-28 | Massachusetts Inst Technology | Compositions and methods for epithelial stem cell expansion and culture |
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、***和方法 |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
EP3400286A1 (en) | 2016-01-08 | 2018-11-14 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
KR20190104359A (ko) | 2016-12-30 | 2019-09-09 | 프리퀀시 테라퓨틱스, 인크. | 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법 |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法 |
EP3906233B1 (en) | 2018-12-31 | 2024-01-31 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5095272A (es) * | 1973-12-24 | 1975-07-29 | ||
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf阻害剤としてのピラゾール |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
JP2005539000A (ja) | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 |
-
2003
- 2003-09-12 OA OA1200500074A patent/OA12925A/en unknown
- 2003-09-12 MX MXPA05002378A patent/MXPA05002378A/es active IP Right Grant
- 2003-09-12 BR BR0314286-8A patent/BR0314286A/pt not_active IP Right Cessation
- 2003-09-12 AU AU2003263431A patent/AU2003263431A1/en not_active Abandoned
- 2003-09-12 EP EP03797466A patent/EP1542995A1/en not_active Withdrawn
- 2003-09-12 AP AP2005003262A patent/AP2005003262A0/xx unknown
- 2003-09-12 KR KR1020057004662A patent/KR20050057441A/ko not_active Application Discontinuation
- 2003-09-12 CN CNA038222043A patent/CN1681809A/zh active Pending
- 2003-09-12 CA CA002499332A patent/CA2499332A1/en not_active Abandoned
- 2003-09-12 PL PL03375973A patent/PL375973A1/xx not_active Application Discontinuation
- 2003-09-12 JP JP2004568905A patent/JP2006506443A/ja not_active Withdrawn
- 2003-09-12 EA EA200500286A patent/EA200500286A1/ru unknown
- 2003-09-12 WO PCT/IB2003/004005 patent/WO2004026865A1/en active Application Filing
- 2003-09-15 TW TW092125380A patent/TW200410954A/zh unknown
- 2003-09-16 UY UY27983A patent/UY27983A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103359A patent/AR041275A1/es unknown
- 2003-09-17 PA PA20038583101A patent/PA8583101A1/es unknown
- 2003-09-17 US US10/667,167 patent/US7030125B2/en not_active Expired - Fee Related
- 2003-09-17 PE PE2003000951A patent/PE20050076A1/es not_active Application Discontinuation
-
2005
- 2005-02-14 IS IS7695A patent/IS7695A/is unknown
- 2005-03-16 HR HR20050246A patent/HRP20050246A2/hr not_active Application Discontinuation
- 2005-03-17 EC EC2005005685A patent/ECSP055685A/es unknown
- 2005-03-18 MA MA28158A patent/MA27444A1/fr unknown
- 2005-03-18 CO CO05025189A patent/CO5550458A2/es not_active Application Discontinuation
- 2005-04-15 NO NO20051852A patent/NO20051852L/no unknown
Also Published As
Publication number | Publication date |
---|---|
MA27444A1 (fr) | 2005-07-01 |
KR20050057441A (ko) | 2005-06-16 |
EP1542995A1 (en) | 2005-06-22 |
HRP20050246A2 (en) | 2005-10-31 |
BR0314286A (pt) | 2005-08-02 |
AU2003263431A1 (en) | 2004-04-08 |
WO2004026865A1 (en) | 2004-04-01 |
US7030125B2 (en) | 2006-04-18 |
CO5550458A2 (es) | 2005-08-31 |
NO20051852L (no) | 2005-06-16 |
UY27983A1 (es) | 2004-04-30 |
TW200410954A (en) | 2004-07-01 |
AR041275A1 (es) | 2005-05-11 |
JP2006506443A (ja) | 2006-02-23 |
US20040116473A1 (en) | 2004-06-17 |
OA12925A (en) | 2006-10-13 |
CN1681809A (zh) | 2005-10-12 |
ECSP055685A (es) | 2005-05-30 |
PA8583101A1 (es) | 2004-04-23 |
CA2499332A1 (en) | 2004-04-01 |
PL375973A1 (en) | 2005-12-12 |
MXPA05002378A (es) | 2005-05-23 |
EA200500286A1 (ru) | 2005-08-25 |
PE20050076A1 (es) | 2005-03-26 |
IS7695A (is) | 2005-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2005003262A0 (en) | Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. | |
AP2005003261A0 (en) | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors. | |
MXPA03008485A (es) | Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7. | |
EP1551801A4 (en) | NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE | |
MXPA03004794A (es) | Derivados de acido mandelico y su uso como inhibidores de trombina. | |
AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
AU2002219555A1 (en) | VLA-4 Inhibitors | |
HUP0301248A3 (en) | Thiadiazole and oxadiazole derivatives, their use as phosphodiesterase-7 inhibitors | |
IL200471A0 (en) | Spinosyn-producing polyketide synthases | |
EP1391502A4 (en) | HOST MICROORGANISMS | |
AP2005003263A0 (en) | Pyrazole derivatives as transforming growth factor(TGF) inhibitors. | |
PL358673A1 (en) | Piperidine coumpounds for use as ccr-3 inhibitors | |
AU2003284399A1 (en) | Plk inhibitors | |
GB9907683D0 (en) | Substituted azetidin-2-ones as cysteine protease inhibitors | |
AU2003212310A1 (en) | (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors | |
AU2003230392A1 (en) | Beta-secretase inhibitors | |
AU2002950316A0 (en) | Plant growth medium | |
AU2002344514A1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
AU1039801A (en) | Compounds and their use as cysteine protease inhibitors | |
HK1057900A1 (en) | 2-Aminothiazoline derivatives and their use as no-synthase inhibitors. | |
EP1437142A4 (en) | MEANS OF INHIBITING CELL GROWTH | |
ZA200205222B (en) | Crystal growth. | |
AU2003231578A1 (en) | Coring tine | |
IL161453A0 (en) | Coal-based organic growth compound | |
GB0128943D0 (en) | Bacterial enzyme inhibitors |